Related Experiment Videos
Debate: Should statin be used in patients with heart failure?
1GISSI Coordinating Center, ANMCO Research Center, Firenze, Italy. maggioni@anmco.it
Insights
Statins, used for coronary artery disease (CAD), were investigated for heart failure patients. This study explored their effects beyond cholesterol reduction in this population.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Statins are proven to reduce mortality in coronary artery disease (CAD) patients.
- Clinical trials have historically excluded patients with chronic heart failure (CHF).
- CAD is a primary cause of heart failure, suggesting statins might impact its progression.
Purpose of the Study:
- To investigate the effects of statins in patients diagnosed with heart failure.
- To explore potential benefits of statins beyond lipid-lowering, such as anti-inflammatory and endothelial function improvements.
- To address the lack of clinical trial evidence regarding statin use in heart failure populations.
Main Methods:
- A controlled trial was designed by the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI).
- The trial focused on patients experiencing heart failure from various underlying causes.
Main Results:
- Conflicting data exists regarding statins' effects in heart failure.
- Potential benefits include anti-inflammatory properties and improved endothelial function.
- Concerns exist about adverse effects on cardiac and skeletal muscles due to mitochondrial function alterations.
Conclusions:
- Evidence from trials on statins in heart failure patients is currently lacking.
- The GISSI trial was initiated to provide crucial data on statin efficacy and safety in this patient group.
Abstract:
Statins reduce mortality of patients with coronary artery disease (CAD). However, by protocol, trials have excluded patients with chronic heart failure. Since the prevalent etiology of heart failure is CAD, preventing CAD may prevent heart failure progression. Statins may have other beneficial effects besides cholesterol lowering, such as anti-inflammatory properties and improvement of endothelial function. On the contrary, high levels of cholesterol can be beneficial in heart failure patients on the basis of the ability of serum lipoproteins to modulate inflammatory response. Furthermore, statins affecting mitochondrial function can have a deleterious effect on skeletal or cardiac muscles. Despite all these conflicting data, there is no evidence from trials on the effects of statins in patients with heart failure. For this reason, the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) investigators planned a controlled trial testing the effect of statins in patients with heart failure of different etiology.